</head> <body style="-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;margin:0;min-width:100%;padding:0;width:100%" data-bg-color="#E9EBF2" bgcolor="#E9EBF2">
CB Partner Webinar 1 hour Vidium {{webinarsautomatedemailsregistrationconfirmation::client_only_logo}} {{webinarsautomatedemailsregistrationconfirmation::client_only_logo_self_hosted}} {{webinarsautomatedemailsregistrationconfirmation::client_only_logo_alt}} {{webinarsautomatedemailsregistrationconfirmation::client_only_logo_width}} {{webinarsautomatedemailsregistrationconfirmation::client_only_logo_custom_css}} {{webinarsautomatedemailsregistrationconfirmation::client_color}} {{webinarsautomatedemailsregistrationconfirmation::supported_by}} In this webinar, explore the clinical application of cancer genomics in canine melanoma. The presentation will begin with an overview of the frequently identified mutations in canine melanoma, followed by a focus on the common therapeutic biomarkers associated with targeted therapies and a deep dive into palbociclib. Become familiar with the mutations commonly identified in canine melanoma and their clinical significance Learn the diagnostic and prognostic utility of mutation information in the clinical management of canine melanoma Understand the canine-specific information for palbociclib, the first in Vidium’s series of targeted therapies, including its pharmacokinetic and toxicology data {{webinarsautomatedemailsregistrationconfirmation::learning_objectives_bullet_4}} {{webinarsautomatedemailsregistrationconfirmation::learning_objectives_bullet_5}} {{webinarsautomatedemailsregistrationconfirmation::learning_objectives_bullet_6}}
Dear #FIRSTNAME#,
Thank you for registering for "#EVENTTITLE#," sponsored by Vidium. Thank you for registering for "#EVENTTITLE#."
In this webinar, explore the clinical application of cancer genomics in canine melanoma. The presentation will begin with an overview of the frequently identified mutations in canine melanoma, followed by a focus on the common therapeutic biomarkers associated with targeted therapies and a deep dive into palbociclib.
If you have any questions for our speaker, you can direct them to support@cliniciansbriefhelp.zendesk.com
Learning Objectives
  • Become familiar with the mutations commonly identified in canine melanoma and their clinical significance
  • Learn the diagnostic and prognostic utility of mutation information in the clinical management of canine melanoma
  • Understand the canine-specific information for palbociclib, the first in Vidium’s series of targeted therapies, including its pharmacokinetic and toxicology data
If you have any questions for our speaker, you can direct them to support@cliniciansbriefhelp.zendesk.com
Webinar Details
#EVENTDAY#, #EVENTDATE#  |  #EVENTTIME# #EVENTTIMEZONESHORT#  |  1 hour
Sponsored by Vidium
Add to Your Calendar
Use the links below to add to your calendar. We'll also send a couple reminders in advance of the webinar.
#CALENDARREMINDER#
How to Join the Webinar
Click the link below to join the webinar. You can join up to 15 minutes before the start time.
#AUDIENCEURL#
Once you click the link, you may be prompted to sign in with the email you used to register (#EMAIL#).
Thank you for registering! We look forward to seeing you.
Sincerely,
The Clinician's Brief Team
The Vidium Team
</head> <body style="-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;margin:0;min-width:100%;padding:0;width:100%" data-bg-color="#E9EBF2" bgcolor="#E9EBF2">
Dear #FIRSTNAME#,
Thank you for registering for "#EVENTTITLE#," sponsored by Vidium. Thank you for registering for "#EVENTTITLE#."
In this webinar, explore the clinical application of cancer genomics in canine melanoma. The presentation will begin with an overview of the frequently identified mutations in canine melanoma, followed by a focus on the common therapeutic biomarkers associated with targeted therapies and a deep dive into palbociclib.
If you have any questions for our speaker, you can direct them to support@cliniciansbriefhelp.zendesk.com
Learning Objectives
  • Become familiar with the mutations commonly identified in canine melanoma and their clinical significance
  • Learn the diagnostic and prognostic utility of mutation information in the clinical management of canine melanoma
  • Understand the canine-specific information for palbociclib, the first in Vidium’s series of targeted therapies, including its pharmacokinetic and toxicology data
If you have any questions for our speaker, you can direct them to support@cliniciansbriefhelp.zendesk.com
Webinar Details
#EVENTDAY#, #EVENTDATE#  |  #EVENTTIME# #EVENTTIMEZONESHORT#  |  1 hour
Sponsored by Vidium
Add to Your Calendar
Use the links below to add to your calendar. We'll also send a couple reminders in advance of the webinar.
#CALENDARREMINDER#
How to Join the Webinar
Click the link below to join the webinar. You can join up to 15 minutes before the start time.
#AUDIENCEURL#
Once you click the link, you may be prompted to sign in with the email you used to register (#EMAIL#).
Thank you for registering! We look forward to seeing you.
Sincerely,
The Clinician's Brief Team
The Vidium Team